- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07661017
GutCheck: Optimization of a Personalized Mobile Health App for Survivors of Gastrointestinal Cancer
16. juni 2026 opdateret af: Masonic Cancer Center, University of Minnesota
There are two components to the study: a patient and a clinician study.
The clinician study will include one-hour semi-structured interviews with oncology specialists to identify facilitators and barriers to integrating digital diet interventions into the clinical workflow, and to understand their needs and preferences for digital diet interventions.
The patient study aims to investigate initial feasibility, efficacy and acceptability of the GutCheck app and intervention.
It will last 9 weeks and involves 2 study visits and 2 active phases with a transition week and optional transition visit between phases.
During active phases, participants will be asked to use the GutCheck app every day.
Prior to the first active phase, participants will go through informed consent and app training.
The first active phase will last two weeks and will focus on tracking participants' diet, gastrointestinal (GI) symptoms, and stress.
The data collected during the first active phase will be used to identify any potential trigger foods that may contribute to GI symptoms, but only if the participant reports experiencing GI symptoms.
Between active phases, participants will have one Transition Week, where results from the first phase are given to the participants with the option to attend a Transition Week Visit.
The second active phase will last four weeks and will involve the message intervention.
A single-blind, micro-randomized trial design will be used to repeatedly randomize participants to different intervention combinations, determining both the timing and frequency of intervention message delivery throughout the day.
Lastly, there will be an exit visit and interview within a week from the intervention to collect post-intervention measures and ask about the participant's experience with the GutCheck app.
Studieoversigt
Status
Ikke rekrutterer endnu
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
200
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Annie W. Lin, PhD, RD
- Telefonnummer: (612) 356 2001
- E-mail: awlin@umn.edu
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ja
Beskrivelse
Inclusion
Survivors of GI cancer are eligible if they are:
- ≥18 years old
- reside in or have received cancer care in Minnesota
- own a smartphone • consent to install the GutCheck app and discontinue diet tracking in other lifestyle apps (e.g., MyFitness, Fitbit, Noom).
- are English-speaking
- have received a GI cancer diagnosis (e.g., esophageal, gastric, colorectal, liver, pancreatic, etc)
- At least 2 months post-cancer treatment
Inclusion criteria for oncology specialists (oncologists, advanced practice providers, nurses, dietitians, and patient navigators) include:
- Have interacted with at least 1 cancer patient or survivor in the past month.
- Have experience working with electronic health records (EHR).
Exclusion
- Currently pregnant (Patient Study ONLY)
- Pregnancy status may be self-reported by the participant.
- Individuals who are postmenopausal, surgically sterile, or otherwise unable to become pregnant are not subject to this exclusion.
- Active cancer or receiving treatment for another cancer.
- Currently taking or has taken antibiotics in the last 3 months.
- Diagnosis of inflammatory bowel disease (e.g., Crohn's Disease, ulcerative colitis), and/or celiac disease.
- Involuntary weight loss of 10% or more of usual body weight within 6 months, or involuntary loss of 5% or more of usual body weight in 1 month.
Oncology specialists' exclusion criteria include:
- Unable to participate in an interview
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Sundhedstjenesteforskning
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Personalization Level - No
The "no personalization" group will receive generic push messages based on United States Department of Agriculture and Centers for Disease Control and Prevention recommendations.
Within their personalization level, participants will be automatically randomized daily to varying message frequency (one vs. three times per day) and timing (preferred times vs. established times).
After each message, all participants will be asked to evaluate whether the message was useful using a 3-point Likert-type visual scale in the app.
|
Participants who were selected to collect their stool samples will be mailed their second kit before the last week (week 8) of intervention.
Participants will collect their stool sample during week 8 and mail them to be processed prior to the Exit Interview Visit.
Participants will be asked to log their food and beverages, stress, and gastrointestinal symptoms daily.
They will also track physical activity.
|
|
Aktiv komparator: Personalization Level - Low
The "low personalization" group will receive similar messages, with occasional use of their names and references to GI cancer.
Within their personalization level, participants will be automatically randomized daily to varying message frequency (one vs. three times per day) and timing (preferred times vs. established times).
After each message, all participants will be asked to evaluate whether the message was useful using a 3-point Likert-type visual scale in the app.
|
Participants who were selected to collect their stool samples will be mailed their second kit before the last week (week 8) of intervention.
Participants will collect their stool sample during week 8 and mail them to be processed prior to the Exit Interview Visit.
Participants will be asked to log their food and beverages, stress, and gastrointestinal symptoms daily.
They will also track physical activity.
|
|
Aktiv komparator: Personalization Level - High
The "high personalization" group messages will be further tailored to age and gender to provide social comparisons.
This group will receive food-related GI messages based on their responses from the personalization quiz during Week 1. Messages will emphasize affordable, commonly available foods to increase likelihood of accessibility.
Within their personalization level, participants will be automatically randomized daily to varying message frequency (one vs. three times per day) and timing (preferred times vs. established times).
After each message, all participants will be asked to evaluate whether the message was useful using a 3-point Likert-type visual scale in the app.
|
Participants who were selected to collect their stool samples will be mailed their second kit before the last week (week 8) of intervention.
Participants will collect their stool sample during week 8 and mail them to be processed prior to the Exit Interview Visit.
Participants will be asked to log their food and beverages, stress, and gastrointestinal symptoms daily.
They will also track physical activity.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Adherence of Diet Tracking
Tidsramme: 1 year
|
Average count of days where the participant tracked at least two episodes a day.
|
1 year
|
|
Adherence of Gastrointestinal (GI) Symptom and Stress Level Tracking
Tidsramme: 1 year
|
Average count of days of GI symptom and stress tracking combination (i.e., once a day for two weeks for both).
|
1 year
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Samarbejdspartnere
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Anslået)
1. december 2026
Primær færdiggørelse (Anslået)
1. juni 2029
Studieafslutning (Anslået)
1. juni 2030
Datoer for studieregistrering
Først indsendt
16. juni 2026
Først indsendt, der opfyldte QC-kriterier
16. juni 2026
Først opslået (Faktiske)
22. juni 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
22. juni 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
16. juni 2026
Sidst verificeret
1. juni 2026
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2025LS135
- MNCCTN038 (Anden identifikator: Minnesota Clinical Trials Network (MNCCTN))
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Gastrointestinal kræft
-
AstraZenecaJohnson & Johnson K.K. Medical CompanyAfsluttetGastrointestinal endoskopi | Gastrointestinal polypektomiJapan
-
Medstar Health Research InstituteRekrutteringGastrointestinal kræft | Gastrointestinal tumor | Gastrointestinal kirurgi | Gastrointestinal tumorkirurgiForenede Stater
-
Pancap Pharma Inc.Nutrasource Pharmaceutical and Nutraceutical Services, Inc.AfsluttetSund og rask | Gastrointestinal fordøjelse | Gastrointestinal velvære | Gastrointestinale kosttilskudCanada
-
University of AarhusMotilis,SwitzerlandAfsluttetMavetømning | Gastrointestinal Motilitet | Total gastrointestinal transittid | Segmentel transittidDanmark
-
Mersin UniversityRekrutteringGastrointestinal motilitetsforstyrrelse | Afføringsforstyrrelse | Gastrointestinal motilitet og afføringsforholdKalkun
-
Massachusetts General HospitalTilmelding efter invitationGastrointestinal dysfunktion | Gastrointestinal sygdomForenede Stater
-
Advanced Endoscopy Research, Robert Wood Johnson...Tilmelding efter invitationGastrointestinal dysfunktion | Galdevejssygdomme | Gastrointestinal kræft | Gastrointestinal sygdom | Pancreas sygdom | Gastrointestinal infektion | Gastrointestinal fistel | Gastrointestinal lidelse | Gastrointestinal skade | Terapeutisk endoskopisk ultralyd | Avanceret endoskopi | Terapeutisk endoskopi | Interventionel... og andre forholdForenede Stater
-
Wecare Probiotics Co., Ltd.Rekruttering
-
Istanbul UniversityRekruttering
-
Second Affiliated Hospital, School of Medicine,...RekrutteringGastrointestinal endoskopiKina
Kliniske forsøg med Stool Sample
-
Hillel Yaffe Medical CenterUkendt
-
University Hospital, MontpellierIkke rekrutterer endnuSund og raskFrankrig
-
Hospices Civils de LyonIkke rekrutterer endnu
-
BiocodexRekruttering